文献速递前列腺癌

卡巴他赛治疗多西他赛经治转移性去势抵抗性前列腺癌的多中心观察研究

An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
PubMed 文献 · BJU Int · 2018-09-16

CAPRISTANA为国际多中心观察性队列研究,纳入189例多西他赛经治的转移性去势抵抗性前列腺癌患者,评估卡巴他赛的实际使用模式、疗效、健康相关生活质量和安全性。结果显示中位总生存13.2个月、无进展生存5.6个月、至治疗失败时间4.4个月,疾病控制率52.9%,72.5%患者生活质量维持或改善,≥3级治疗相关不良事件以中性粒细胞减少(7.9%)和贫血(2.1%)最常见。

要点

  • 卡巴他赛二线治疗mCRPC的中位OS为13.2个月、PFS为5.6个月。
  • 疾病控制率达52.9%,72.5%患者生活质量维持或改善。
  • ≥3级治疗相关不良事件以中性粒细胞减少(7.9%)和贫血(2.1%)为主。

核心结论

  • CAPRISTANA中接受卡巴他赛治疗的患者疾病结局和安全性特征与大型III期临床试验相似。
  • 多数患者健康相关生活质量评分维持或改善,超过70%患者疼痛控制维持或改善。

研究设计与样本

  • CAPRISTANA为国际、观察性队列研究,评估卡巴他赛治疗mCRPC的使用模式、医生评估的疗效、健康相关生活质量和安全性。
  • 2012年4月至2016年6月期间,54个中心共189例患者接受治疗。

主要发现

  • 基线时58.7%有至少1种合并症,93.7%的ECOG体能状态评分≤1,60.1%诊断时Gleason评分≥8。
  • 患者接受卡巴他赛中位6个周期,84.7%作为二线治疗。
  • 中位OS、PFS和TTF分别为13.2、5.6和4.4个月,疾病控制率52.9%。
  • 基于FACT-P总评分,72.5%患者生活质量维持(40.3%)或改善(32.2%)。
  • 基于FACT-P前列腺癌特异性疼痛评分,53.6%患者疼痛改善,另有21.2%维持疼痛控制。

关键数值与推荐

  • 最常见治疗相关≥3级不良事件为中性粒细胞减少(7.9%)和贫血(2.1%)。

临床怎么用

  • 卡巴他赛用于多西他赛经治的mCRPC患者,实际临床中疗效与安全性与III期试验一致。
  • 治疗期间多数患者生活质量和疼痛控制得以维持或改善,支持其作为二线治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To obtain routine clinical practice data on cabazitaxel usage patterns for patients with metastatic castration-resistant prostate cancer (mCRPC) and to describe physician-assessed cabazitaxel effectiveness, health-related quality of life (HRQoL) and safety. PATIENTS AND METHODS: CAPRISTANA was an international, observational cohort study examining cabazitaxel use for the treatment of patients with mCRPC. Effectiveness was assessed by overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF) and disease control rate. HRQoL was assessed using the Functional Assessment of Cancer Therapy-Prostate questionnaire (FACT-P) and the three-level European Quality of Life questionnaire (EQ-5D-3L). Safety was assessed by adverse event (AE) reporting. RESULTS: A total of 189 patients were treated across 54 centres between April 2012 and June 2016. At baseline, 58.7% had ≥1 comorbidity, 93.7% had an Eastern Cooperative Oncology Group performance status ≤1, and 60.1% had a Gleason score at diagnosis of ≥8. Patients received a median of 6 cabazitaxel cycles; 84.7% received cabazitaxel as second-line therapy. The median OS, PFS and TTF were 13.2, 5.6 and 4.4 months, respectively. Cabazitaxel led to disease control in 52.9% of patients. HRQoL was maintained (40.3%) or improved (32.2%) in 72.5% of patients based on total FACT-P scores. Interestingly, 53.6% of patients reported pain improvement and a further 21.2% maintained pain control based on FACT-P prostate cancer-specific pain scores. The most common treatment-related grade ≥3 AEs were neutropenia (7.9%) and anaemia (2.1%). CONCLUSION: Patients in CAPRISTANA treated with cabazitaxel had similar disease outcomes and safety profiles compared with large phase III clinical trials. Most patients had maintained or improved HRQoL scores; >70% of patients had maintained or improved pain control.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Carles J, Pichler A, Korunkova H, et al. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA). BJU Int. 2018. PMID: 30098093. doi:10.1111/bju.14509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。